Private company

Evoke Pharma Inc

We are a specialty pharmaceutical company focused primarily on the development and commercialization of drugs to treat gastrointestinal (“GI”) disorders and diseases.4 From its latest annual report

Last updated Oct 19, 2026.

Overview

  • IndustryPharmaceutical Preparations2
  • HeadquartersSolana Beach, United States2
  • Incorporated inDE3
  • Business address420 Stevens Avenue, Suite 230, Solana Beach, Ca 920753
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI529900Q01Z5E3L6MZZ662
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressc/o CORPORATION SERVICE COMPANY, 251 LITTLE FALLS DRIVE, 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 42923922

See how the biggest companies compare on our leaderboards

We are a specialty pharmaceutical company focused primarily on the development and commercialization of drugs to treat gastrointestinal (“GI”) disorders and diseases. Since our inception, we have devoted our efforts to developing our sole product, Gimoti ® (metoclopramide) nasal spray, the first and only nasally-administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. In June 2020, we received approval from the United States Food and Drug Administration (“FDA”) for our 505(b)(2) New Drug Application for Gimoti (the “Gimoti NDA”). We launched commercial sales of Gimoti in the United States in October 2020 through our commercial partner, Eversana Life Science Services, LLC (“Eversana”).4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

-50.8%Operating margin5
-52.2%Net margin5
97.8%Revenue growth, 20245
-76.0%Return on equity5

Where the money goes

Where each dollar of revenue went, fiscal 2024

  • Selling, general and admin97¢$15.1M
  • Interest3¢$501.4K

Out of $10.2M in revenue.5 The company lost money this year.

Financial statements

Revenue6785$10.2M in 2024+44424% since 2020
0$5.0M$10.0M$15.0M2020: $23.0K$23.0K20202021: $1.6M$1.6M2021+6929%2022: $2.5M$2.5M2022+55%2023: $5.2M$5.2M2023+107%2024: $10.2M$10.2M2024+98%
Operating income9106785-$5.2M in 2024−35% since 2018
-$15.0M-$10.0M-$5.0M02018: -$8.0M-$8.0M20182019: -$7.2M-$7.2M2019−11%2020: -$13.0M-$13.0M2020+82%2021: -$8.2M-$8.2M2021−38%2022: -$7.8M-$7.8M2022−4%2023: -$7.4M-$7.4M2023−5%2024: -$5.2M-$5.2M2024−30%
Net income910675-$5.4M in 2024−29% since 2018
-$15.0M-$10.0M-$5.0M02018: -$7.6M-$7.6M20182019: -$7.1M-$7.1M2019−6%2020: -$13.2M-$13.2M2020+85%2021: -$8.5M-$8.5M2021−35%2022: -$5.4M-$5.4M2022−37%2023: -$7.8M-$7.8M2023+46%2024: -$5.4M-$5.4M2024−31%
Fiscal year2018201920202021202220232024
Revenue$23.0K6$1.6M7$2.5M8$5.2M5$10.2M5
Selling, general and admin$3.7M10$6.4M6$8.9M7$9.6M8$12.2M5$15.1M5
Operating expenses$9.8M7$10.3M8$12.6M5$15.5M5
Operating income-$8.0M9-$7.2M10-$13.0M6-$8.2M7-$7.8M8-$7.4M5-$5.2M5
Interest$113.0K6$500.1K7$500.0K8$500.0K5$501.4K5
Net income-$7.6M9-$7.1M10-$13.2M6-$8.5M7-$5.4M5-$7.8M5-$5.4M5
Earnings per share-$0.4613-$3.187-$2.628-$27.975-$2.815
Earnings per share (diluted)-$0.4613-$3.187-$2.628-$27.975-$2.815
Shares (weighted, basic)2.7M shares73.1M shares8278.6K shares51.9M shares5
Shares (weighted, diluted)2.7M shares73.1M shares8278.6K shares51.9M shares5

Compare Evoke Pharma Inc with another company

Leadership

Who has led Evoke Pharma Inc, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. David A. Gonyer2013–2023
  2. Matthew J. D'Onofrio2024–now

President

  1. David A. Gonyer2013–2022
  2. Matthew J. D'Onofrio2023

Chief financial officer

  1. Mark Kowieski2024–now
201520202025
Board members and other officers (13)

Timeline

  1. Aug 8, 2024New chief executive Matthew J. D'Onofrio becomes CEO15
  2. Sep 24, 2013New chief executive David A. Gonyer becomes CEO16

Filings

247 filings to the SEC since October 2021: 5 annual reports, 13 quarterly reports, 69 major events, 62 insider forms, 19 large holders, 79 other. The latest 20:

  1. Dec 30, 202515-12G EDGAR
  2. Dec 19, 2025SCHEDULE 13D/A EDGAR
  3. Dec 19, 20254 OWNERSHIP DOCUMENT EDGAR
  4. Dec 18, 2025EFFECT EDGAR
  5. Dec 18, 2025EFFECT EDGAR
  6. Dec 18, 2025EFFECT EDGAR
  7. Dec 18, 2025EFFECT EDGAR
  8. Dec 18, 2025EFFECT EDGAR
  9. Dec 18, 2025EFFECT EDGAR
  10. Dec 17, 2025S-8 POS EDGAR
  11. Dec 17, 2025S-8 POS EDGAR
  12. Dec 17, 2025S-8 POS EDGAR
  13. Dec 17, 2025S-8 POS EDGAR
  14. Dec 17, 2025S-8 POS EDGAR
  15. Dec 17, 2025POS AM EDGAR
  16. Dec 17, 2025POS AM EDGAR
  17. Dec 17, 2025POS AM EDGAR
  18. Dec 17, 2025POS AM EDGAR
  19. Dec 17, 2025POS AM EDGAR
  20. Dec 17, 2025POS AM EDGAR

The 247 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

2 open-market trades by officers, directors and large owners since October 2021: 0 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 6, 2025Klein Roger M.10% ownerSale9,000$10.66$95.9KForm 4
Jan 28, 2025Mack Daniel10% ownerSale41$4.39$180Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36